Onglyza Heart Failure Side Effects
The FDA issued a warning this week, indicating that the agency is reviewing the potential side effects of Onglyza, a diabetes drug that has been linked to an increased risk of heart failure.
The lawyers at Saiontz & Kirk, P.A. are already reviewing potential Onglyza lawsuits for former users of the incretin mimetic diabetes diagnosed with pancreatic cancer. The potential for cases over Onglyza heart failure are also now being reviewed and evaluated.
If you, a friend or family member have been diagnosed with heart failure after use of Onglyza, submit information about your potential claim for consideration as we evaluate whether individuals may be entitled to financial compensation as a result of the drug makers’ failure to provide adequate warnings.
▸ SUBMIT INFORMATION ABOUT AN ONGYLZA HEART INJURY
On February 11, the FDA announced that it is launching a drug safety investigation into the Onglyza heart failure risks after a 2013 study indicated that patients given the type 2 diabetes drug may be more likely to be hospitalized due to heart failure. The FDA has asked for the manufacturers, AstraZeneca and Bristol-Myers Squibb, to turn over relevant clinical data.
Concerns over Onglyza heart problems have shadowed the drug since it was first approved in 2009. However, it was a study funded by the manufacturers themselves that appears to show that the drug increases the risk of heart failure. That study, published in October 2013 in the New England Journal of Medicine, was originally meant to look for heart benefits from using Onglyza.
While the study found no increased risk of death, it did find that 3.5% of Onglyza users suffered heart failure, compared to only 2.8 percent of those given a placebo.
As the FDA continues to investigate this matter, the Onglyza lawyers at Saiontz & Kirk, P.A. are reviewing the publicly available data and evaluating whether individuals who suffered heart failure may be entitled to financial compensation through a product liability lawsuit.
Potential Onglyza pancreatic cancer cases are already being reviewed on behalf of individuals throughout the United States, presenting claims that the drug maker placed their desire for profits before the safety of consumers by withholding information about the side effects of Onglyza on the pancrease.
To have information about a case of heart failure suffered by yourself, a friend or family member included as part of our review of this potential litigation, request a free consultation and claim evaluation.
No Comments • Add Your Comments